Breast Journal最新文献

{"title":"Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers","authors":"Atif Ali Hashmi, Yumna Ajaz, Muhsana Sajjad, Fazail Zia, Muhammad Irfan, Syed Muhammad Abu Bakar, Erum Yousuf Khan, Naveen Faridi","doi":"10.1155/tbj/8410670","DOIUrl":"https://doi.org/10.1155/tbj/8410670","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Triple-negative breast cancers (TNBCs) constitute a significant proportion of breast cancers in Pakistan. Owing to the lack of expression of hormone (estrogen/progesterone) receptor and human epidermal growth factor receptor 2 (HER2neu), treatment options for TNBCs are limited. Therefore, it is important to identify markers that predict response to chemotherapy in these patients. Previous studies have demonstrated that the excision repair cross complementation group 1 (ERCC1) protein can successfully augur the response to chemotherapy in cancer; however, data related to TNBCs, particularly in Pakistan, are limited. Therefore, in this study, we evaluated the role of ERCC1 in predicting the response to neoadjuvant chemotherapy in patients with TNBCs.</p>\u0000 <p><b>Methods:</b> This cross-sectional study was conducted at the Liaquat National Hospital, Histopathology Department, between January 2019 and June 2023. A total of 132 biopsy-proven cases of breast cancer that were negative for estrogen receptor (ER), progesterone receptor (PR), and HER/2neu and were administered neoadjuvant chemotherapy before surgery were included in the study. ERCC1 immunohistochemical (IHC) staining was performed on prechemotherapy needle biopsies. The results were scored semiquantitatively by assessing the average intensity on a scale of 0–3 (0, no staining; 1, weak nuclear staining; 2, intermediate nuclear staining; and 3, strong nuclear staining) and the proportion of tumor cells showing positive nuclear staining. The intensity and proportion scores were then multiplied to give a score that was divided by 100 to give an overall score, and scores equal to or higher than 1.0 were considered positive. Neoadjuvant chemotherapy response was categorized as pathological complete response (pCR) when no residual invasive breast carcinoma was found on the postneoadjuvant chemotherapy excision specimen and as pathological partial response (pPR) when residual cancer cells were present in admixed chemotherapy-related changes. The residual cancer burden (RCB) was calculated using the MD Anderson RCB calculator. The association between ERCC1 expression and the chemotherapy response/RCB class was determined.</p>\u0000 <p><b>Results:</b> We found that 90.9% (<i>n</i> = 120) of TNBC cases expressed ERCC1, whereas pCR was noted in 24 (18.2%) cases. A significant association was observed between ERCC1 expression and pCR. Cases with negative ERCC1 expression had a significantly higher frequency of pCR (66.7%) than those with positive ERCC1 expression (13.3%). Additionally, the ERCC1-positive group showed a higher frequency of RCB classes II (36.7%) and III (43.3%) than the ERCC1-negative group (RCB II: 25%; RCB III: 0%). Moreover, positive ERCC1 expression was associated with higher nodal (N) stage.</p>\u0000 <p><b>Conclusion:</b> In this study, we established the role of negative ERCC1 expression in predicting the response to","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/8410670","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Risk of Haematoma and Venous Thrombosis Associated With Thromboprophylaxis Use in Breast Cancer Surgery: A Meta-Analysis and Systematic Review","authors":"Amenah Dhannoon,&nbsp;Ishwarya Balasubramanian,&nbsp;Ali A. Dhannoon,&nbsp;Abeeda Butt,&nbsp;Arnold D. K. Hill","doi":"10.1155/tbj/9898596","DOIUrl":"https://doi.org/10.1155/tbj/9898596","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> The routine use of venous thromboembolism (VTE) prophylaxis in breast cancer surgery has caused substantial polarity among breast cancer surgeons across the globe. The aim of this study is to assess the use of VTE prophylaxis in breast cancer surgery outcomes.</p>\u0000 <p><b>Methods:</b> A comprehensive electronic search was undertaken of all comparative studies that described the role of VTE prophylaxis in breast cancer surgery. Studies that reported on postoperative outcomes between patients who received VTE prophylaxis (prophylaxis) and those who did not (no prophylaxis) were included in the review. A meta-analysis using random-effect model was used to analyse key outcomes, with data presented as odd ratio (OR).</p>\u0000 <p><b>Results:</b> A total of 2470 patients from 6 studies were included in this study. Among these patients, 60.9% (<i>n</i>: 1504) received prophylaxis. The haematoma rate in this study is 0.05% (<i>n</i>: 133). The incidence of haematoma was significantly associated with the use of prophylaxis (6.85% versus 3.11%, <i>p</i> : 0.001). Surgical intervention for haematomas was also significantly associated in this group (3.15% versus 0.83%, <i>p</i> : 0.004). However, there was no difference in VTE events between both groups (0.26% versus 0.36%, <i>p</i> : 0.88).</p>\u0000 <p><b>Conclusions:</b> The use of VTE prophylaxis in breast cancer surgery is associated with increased haematomas without any benefit in preventing VTE events. Future studies that examine the use of risk assessment tools for VTE prophylaxis in high risk patients may be beneficial.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9898596","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143112054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between Clinicopathological Features and Prognosis of 22 Cases of Tubular Breast Carcinoma","authors":"Lin Tian,&nbsp;Xiangchao Meng,&nbsp;Huiyan Si,&nbsp;Yue Qiu,&nbsp;Rui Qu,&nbsp;Hongye Chen","doi":"10.1155/tbj/5599018","DOIUrl":"https://doi.org/10.1155/tbj/5599018","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Breast tubular carcinoma is a special pathological type of invasive breast cancer, accounting for about 0.8% to 10.0% of breast cancer cases, and it is a rare type of breast cancer. Currently, there is still a lack of relevant diagnostic and treatment consensus. Exploring the relationship between the pathological characteristics, molecular subtypes, and prognosis of ductal breast cancer is of great scientific value and clinical significance for improving patients’ survival rate and quality of life.</p>\u0000 <p><b>Methods:</b> The clinical data of 22 patients with tubular breast carcinoma diagnosed by pathology in The First Medical Center of PLA General Hospital from January 2001 to December 2021 were collected, and their pathological features, molecular classification, and prognosis were analyzed retrospectively.</p>\u0000 <p><b>Results:</b> The clinicopathological features of 22 patients with tubular breast carcinoma were age ≥ 35 years, married, tumor ≤ 2 cm, single focal, mixed type, no lymph node metastasis, estrogen receptor (ER) positive, progesterone receptor (PR) positive, Ki-67 ≤ 14%, CyclinD1 negative, less recurrence, and metastasis. Twenty-two patients with breast tubular carcinoma were followed up for 5 years after surgery, and the survival rate of disease-free survival (DFS) was 90.9% (20/22). The positive rates of ER, PR, and human epidermal growth factor receptor-2 (HER-2) are 100.0%, 100.0%, and 40.9%, respectively. The proportion of tumor cells expressing Ki-67 is 45.4%. Among them, the difference of HER-2 level, recurrence and metastasis, and postoperative comprehensive treatment showed different prognoses.</p>\u0000 <p><b>Conclusion:</b> Tubular breast carcinoma is a kind of tumor with a low malignant degree. The prognosis is significantly related to its HER-2 level, recurrence and metastasis, and postoperative comprehensive treatment by univariate analysis, in which HER-2 is an independent risk factor, postoperative comprehensive treatment is a protective factor, but postoperative recurrence and metastasis have nothing to do with the prognosis by the multivariate analysis.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/5599018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143111263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Switching to Tumescent Dissection in Mastectomy","authors":"Emna Bakillah,&nbsp;Ari D. Brooks,&nbsp;Seye Adekeye","doi":"10.1155/tbj/7634729","DOIUrl":"https://doi.org/10.1155/tbj/7634729","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Tumescent dissection (TUM) combines the use of crystalloid, local anesthetic, and epinephrine to create a bloodless plane to raise skin flaps. We aim to compare outcomes of TUM versus standard electrocautery dissection in mastectomies with and without reconstruction.</p>\u0000 <p><b>Methods:</b> We conducted a retrospective cohort study of patients who underwent mastectomy by a single surgeon between January 2016 and October 2020 utilizing the electronic medical record. The primary outcome was complication rate, and the secondary outcome was operative time. Chi-squared analysis and two-sample <i>t</i>-tests were used to examine outcomes.</p>\u0000 <p><b>Results:</b> Among 242 patients, 141 patients underwent TUM and 101 patients underwent electrocautery. 44.68% of TUM patients experienced one or more complications compared to 59.41% of electrocautery patients (<i>p</i> = 0.024). There were fewer cases of wound healing complications in the TUM group with reconstruction compared to the electrocautery group with reconstruction (6.1% vs. 21%, <i>p</i> = 0.005). Infection rate was higher in the TUM group with reconstruction compared to the electrocautery group with reconstruction (14.3% vs. 3.2%, <i>p</i> = 0.023). There was no significant difference in rates of hematoma, seroma, skin flap necrosis, nipple areolar complex necrosis, or re-exploration by dissection technique. The mean operative time was shorter with TUM compared to electrocautery (216.09 min vs. 250.16 min, <i>p</i> = 0.016).</p>\u0000 <p><b>Conclusion:</b> TUM yields comparable results with decreased overall complication rates compared to electrocautery dissection. Electrocautery thermal effect may account for skin-related complications. Additionally, tumescent mastectomies have shorter length of operative time which could reduce the risk of complications associated with increased time under general anesthesia.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/7634729","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Idiopathic Granulomatous Mastitis: Effectiveness of a Steroid-Free Regimen Using Tinospora cordifolia—A Single-Institution Experience","authors":"Ankita Das Sheth,&nbsp;Shalaka Joshi,&nbsp;Arul Kumar,&nbsp;Nita Nair,&nbsp;Tanuja Shet,&nbsp;Ayushi Sahay,&nbsp;Palak Thakkar,&nbsp;Purvi Haria,&nbsp;Aparna Katdare,&nbsp;Vani Parmar,&nbsp;Sangeeta Desai,&nbsp;Rajendra Badwe","doi":"10.1155/tbj/2997891","DOIUrl":"10.1155/tbj/2997891","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Idiopathic granulomatous mastitis (IGM) is a benign, chronic inflammatory disease with no effective treatment and high relapse rate. The pathophysiology is poorly understood. Tinosporin, an immunomodulator obtained from <i>Tinospora cordifolia</i>, is known to be useful in treating immune-mediated diseases. We report our experience of using Tinosporin for IGM and the effectiveness of this “steroid-free” regimen.</p>\u0000 <p><b>Methods:</b> We analysed the clinicopathological characteristics of patients diagnosed with IGM on histopathology during January 2018 and December 2022. Tinosporin tablet (500 mg Guduchi stem extract) was prescribed for 3–6 months; data were collected from electronic medical records and analysed in SPSS v-29.</p>\u0000 <p><b>Results:</b> Of 315 patients, 132 had complete clinical records. Median age was 39 years (25–77), and 107 (81.7%) were premenopausal. Seventy-eight (59.09%) had clinical suspicion of malignancy. On imaging, 84 (63.64%) were BIRADS 4/5 lesions. Empirical broad-spectrum antibiotics were prescribed to 101 patients. Tinosporin tablets were prescribed to 91 patients. Symptomatic response was seen in 72 (79.12%). Five patients did not achieve response, while 14 patients (15.38%) were lost to follow-up. At a median follow-up of 36 months (14–62 months), only 2 patients on Tinosporin had recurrence. None of the patients needed surgical intervention other than diagnostic biopsy or control of infection, and none received steroids.</p>\u0000 <p><b>Conclusion:</b> IGM is a benign, often self-limiting disorder. However, it mimics malignancy in 60% cases, and histology clinches the diagnosis. We report the efficacy of steroid-free management of IGM with immunomodulatory herbal origin phytopharmaceutical drug Tinosporin. It is safe, inexpensive and effective. Large volume excisions or mastectomies can be reserved for severe and refractory cases.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intralesional Steroid Injections for Management of Granulomatous Mastitis: A Systematic Review of Treatment Protocols and Clinical Outcomes","authors":"J. Vercoe,&nbsp;N. Sedaghat,&nbsp;M. E. Brennan","doi":"10.1155/tbj/2592366","DOIUrl":"10.1155/tbj/2592366","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Although idiopathic granulomatous mastitis (GM) of the breast is a benign condition, it can be locally aggressive and frequently chronic, causing significant pain and distress to the patient. Treatment often involves multiple disciplines including general practice, breast surgery/physicians, rheumatology and/or immunology. Traditional options for treatment include observation, oral steroids, methotrexate and/or surgery, all with variable outcomes. A more recent alternative treatment option involves intralesional steroid injections.</p>\u0000 <p><b>Methods:</b> Using PRISMA methodology, a systematic review of intralesional steroid injection for the management of GM was conducted. Medline, PubMed, Embase and Cochrane databases were searched for original studies reporting treatment protocols and clinical outcomes, published up to the end of September 2023.</p>\u0000 <p><b>Results:</b> Nine eligible studies reported outcomes in 474 patients undergoing treatment of GM with intralesional injections. All studies reported success (improvement in clinical and/or imaging appearance) with intralesional injections. Studies that had a comparison group showed statistically significantly fewer side effects compared to oral steroids or surgical management. The recurrence rate was less for intralesional injections than for other treatments in all studies except one. No studies included patient-reported outcomes.</p>\u0000 <p><b>Conclusion:</b> There is consistent evidence for the safety, efficacy and low recurrence rate with intralesional steroid injections for GM. The existing literature is heterogenous with respect to injection protocols, and the optimal protocol is unclear. Future research should compare the various steroid agents and dose/frequency of administration. Future studies should include cost analysis and patient-reported outcomes to ensure that the treatment is cost-effective and acceptable to people with idiopathic GM.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOTIFICATION: Development of a Novel Approach for Breast Cancer Prediction and Early Detection Using Minimally Invasive Procedures and Molecular Analysis: How Cytomorphology Became a Breast Cancer Risk Predictor","authors":"The Breast Journal","doi":"10.1155/tbj/9806762","DOIUrl":"https://doi.org/10.1155/tbj/9806762","url":null,"abstract":"<p><b>NOTIFICATION:</b> S. Masood, “Development of a Novel Approach for Breast Cancer Prediction and Early Detection Using Minimally Invasive Procedures and Molecular Analysis: How Cytomorphology Became a Breast Cancer Risk Predictor,” <i>The Breast Journal</i> 21, no. 1 (2015): 82–96, https://doi.org/10.1111/tbj.12362.</p><p>This notification is for the above article, published online on 04 January 2015 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Dr. Guan-Jun Yang, and John Wiley &amp; Sons Ltd. Following an investigation, the parties learned that an independent peer review process was not conducted for this article prior to publication. The current Editor-in-Chief of the journal, Dr. Guan-Jun Yang, has subsequently reviewed the content of the article and determined that it is suitable to remain published, noting that it does not represent original research, but primarily an editorial contribution from the previous Editor-in-Chief, Dr. Shahla Masood. Therefore, the parties have decided to issue this notification to inform and alert readers.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9806762","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOTIFICATION: Is it Ductal Carcinoma in Situ with Microinvasion or “Ductogenesis”? The Role of Myoepithelial Cell Markers","authors":"The Breast Journal","doi":"10.1155/tbj/9820169","DOIUrl":"https://doi.org/10.1155/tbj/9820169","url":null,"abstract":"<p><b>NOTIFICATION:</b> S. Masood, “Is it Ductal Carcinoma in Situ with Microinvasion or “Ductogenesis”? The Role of Myoepithelial Cell Markers” <i>The Breast Journal</i> 26, no. 6 (2020): 1138–1147, https://doi.org/10.1111/tbj.13897.</p><p>This notification is for the above article, published online on 23 May 2020 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Dr. Guan-Jun Yang, and John Wiley &amp; Sons Ltd. Following an investigation, the parties learned that an independent peer review process was not conducted for this article prior to publication. The current Editor-in-Chief of the journal, Dr. Guan-Jun Yang, has subsequently reviewed the content of the article and determined that it is suitable to remain published, noting that it does not represent original research, but primarily an editorial contribution from the previous Editor-in-Chief, Dr. Shahla Masood. Therefore, the parties have decided to issue this notification to inform and alert readers.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9820169","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOTIFICATION: The Role of Pathologists in Recognition of Morphologic and Biologic Features of Genetically Mutated Breast Cancer","authors":"The Breast Journal","doi":"10.1155/tbj/9823045","DOIUrl":"https://doi.org/10.1155/tbj/9823045","url":null,"abstract":"<p><b>NOTIFICATION:</b> S. Masood, “The Role of Pathologists in Recognition of Morphologic and Biologic Features of Genetically Mutated Breast Cancer” <i>The Breast Journal</i> 26, no. 8 (2020): 1583–1588, https://doi.org/10.1111/tbj.14012.</p><p>This notification is for the above article, published online on 26 August 2020 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Dr. Guan-Jun Yang, and John Wiley &amp; Sons Ltd. Following an investigation, the parties learned that an independent peer review process was not conducted for this article prior to publication. The current Editor-in-Chief of the journal, Dr. Guan-Jun Yang, has subsequently reviewed the content of the article and determined that it is suitable to remain published, noting that it does not represent original research, but primarily an editorial contribution from the previous Editor-in-Chief, Dr. Shahla Masood. Therefore, the parties have decided to issue this notification to inform and alert readers.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9823045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOTIFICATION: The Changing Role of Pathologists from Morphologists to Molecular Pathologists in the Era of Precision Medicine","authors":"The Breast Journal","doi":"10.1155/tbj/9815069","DOIUrl":"https://doi.org/10.1155/tbj/9815069","url":null,"abstract":"<p><b>NOTIFICATION:</b> S. Masood, “The Changing Role of Pathologists from Morphologists to Molecular Pathologists in the Era of Precision Medicine,” <i>The Breast Journal</i> 26, no. 1 (2019): 27–34, https://doi.org/10.1111/tbj.13728.</p><p>This notification is for the above article, published online on 25 December 2019 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Dr. Guan-Jun Yang, and John Wiley &amp; Sons Ltd. Following an investigation, the parties learned that an independent peer review process was not conducted for this article prior to publication. The current Editor-in-Chief of the journal, Dr. Guan-Jun Yang, has subsequently reviewed the content of the article and determined that it is suitable to remain published, noting that it does not represent original research, but primarily an editorial contribution from the previous Editor-in-Chief, Dr. Shahla Masood. Therefore, the parties have decided to issue this notification to inform and alert readers.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9815069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}